S'abonner

Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity - 14/06/13

Doi : 10.1016/j.jaad.2013.01.010 
Yvonne E. Chiu, MD a, , Peter L. Havens, MD, MS b, Dawn H. Siegel, MD a, Omar Ali, MD c, Tao Wang, PhD d, Kristen E. Holland, MD a, Sheila S. Galbraith, MD a, Valerie B. Lyon, MD e, Beth A. Drolet, MD a
a Department of Dermatology, Division of Pediatric Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin 
b Department of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, Wisconsin 
c Department of Pediatrics, Division of Endocrinology, Medical College of Wisconsin, Milwaukee, Wisconsin 
d Institute for Health and Society, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin 
e Madison Medical Affiliates, Milwaukee, Wisconsin 

Correspondence to: Yvonne E. Chiu, MD, Department of Dermatology, 8701 Watertown Plank Rd, Milwaukee, WI 53226.

Abstract

Background

An inverse correlation between serum 25-hydroxyvitamin D concentration and atopic dermatitis (AD) severity has been suggested.

Objective

To determine if a statistically significant relationship exists between serum 25-hydroxyvitamin D concentration and AD severity.

Methods

A cross-sectional study was conducted of patients with AD who were 1 to 18 years of age. An objective Severity Scoring of Atopic Dermatitis (SCORAD) and a serum 25-hydroxyvitamin D concentration were measured for each subject. Statistical analysis was performed using appropriate univariate tests and multivariable models.

Results

Ninety-four of 97 enrolled subjects were included in the analysis. Vitamin D deficiency (25-hydroxyvitamin D <20 ng/mL) was present in 37 subjects (39%), insufficiency (25-hydroxyvitamin D 21-29 ng/mL) in 33 (35%), and sufficiency (25-hydroxyvitamin D ≥30 ng/mL) in 24 (26%). The correlation between 25-hydroxyvitamin D concentration and SCORAD was not significant (r = –0.001; P = .99). A multivariate model showed that a lower serum 25-hydroxyvitamin D concentration was significantly associated with age 3 years or older (P < .0001), black race (P < .0001), and winter season (P = .0084).

Limitations

Limitations of this study include the inability to control for natural sunlight exposure, vitamin D intake, and AD treatment; in addition, only a single time point was captured.

Conclusions

Serum 25-hydroxyvitamin D concentration is not significantly correlated with AD severity in our pediatric population.

Le texte complet de cet article est disponible en PDF.

Key words : asthma, atopic dermatitis, atopy, eczema, 25-hydroxyvitamin D, vitamin D

Abbreviations used : 1,25(OH)2D, 25(OH)D, AD, SCORAD


Plan


 Funding sources: This project was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant number UL1RR031973. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Additional support was received from the Russell and Betty Jane Shaw Fund of the Greater Milwaukee Foundation.
 Disclosure: Dr Galbraith serves on an advisory board for Valeant Pharmaceuticals.
 This work has previously been presented in poster format at the 38th Annual Meeting of the Society for Pediatric Dermatology.
 Conflicts of interest: None declared.


© 2013  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 69 - N° 1

P. 40-46 - juillet 2013 Retour au numéro
Article précédent Article précédent
  • Atopic dermatitis–like presentation of graft-versus-host disease: A novel form of chronic cutaneous graft-versus-host disease
  • Jin Wei, Yu Zhang, Hongjun Xu, Jiang Jin, Jianzhong Zhang
| Article suivant Article suivant
  • Visual images for patient skin self-examination and melanoma detection: A systematic review of published studies
  • Jennifer E. McWhirter, Laurie Hoffman-Goetz

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.